Pruritus may impair quality of life in patients with Sézary syndrome, the leukemic variant of cutaneous T-cell lymphomas. Management of pruritus is challenging and often unsatisfactory. Retrospective reports have found aprepitant, a neurokinin 1 receptor antagonist approved for the treatment of chemotherapy-induced or postoperative emesis, to show some efficacy in managing pruritus in patients with cutaneous T-cell lymphoma. [1] [2] [3] [4] [5] We conducted a randomized, double-blind, placebocontrolled crossover study in patients with Sézary syndrome to test the hypothesis that treatment with the neurokinin 1 receptor antagonist aprepitant would decrease pruritus.
Methods | Patients seen in the Vanderbilt University Cutaneous Lymphoma clinic meeting the International Society for Cutaneous Lymphomas-European Organisation for Research and Treatment of Cancer criteria
6 for Sézary syndrome were eligible. Patients with Sézary syndrome with uncontrolled pruritus and a baseline visual analog scale for pruritus of greater than 40 mm were eligible. Participants were also required to be on a stable medication regimen for Sézary syndrome and a stable antipruritic medication regimen for 3 months prior to the study. Written informed consent was obtained and the protocol was approved by the Vanderbilt Institutional Review Board and carried out according to the Declaration of Helsinki. The study protocol is available in the Supplement. Placebo or aprepitant (125 mg on day 1, followed by 80 mg on days 2-7) was ingested daily for 7 days followed by a 1-week washout period before taking the other treatment. The primary outcome measure was severity of pruritus measured using a visual analog scale of 0 to 100 mm (worst pruritus imaginable). The secondary outcome measure was quality of life using the Dermatology Life Quality Index instrument. Mixed-effect models were used to analyze the data with a random subject effect and with treatment (aprepitant vs placebo) and time as fixed effects; baseline pruritus by visual analog scale was included as a covariate. Paired comparisons at specific time points or between time points were made using a Wilcoxon signed-rank test. Hypotheses were tested at the level of α = .05.
Results | Five patients were randomized to therapy and completed the study. The Table provides characteristics of the patients. All of the patients had been treated with more than 1 medication, and all were undergoing photopheresis.
There were no differences in quality-of-life measures between the 2 interventions. Pruritus did not change over 7 days of treatment in the placebo arm but increased significantly during the aprepitant treatment ( Figure) . In multivariable analysis, baseline pruritus (every 10 unit increment, 7.20; 95% CI, 5.98-8.44; P < .001) and treatment (10.63; 95% CI, 3.49-17.77; P = .004) had a significant effect on pruritus over the 7-day treatment period.
Discussion | To our knowledge, we report herein the results of the first randomized, double-blind, placebo-controlled 
P<.001
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A score of 100 mm indicated the worst pruritus imaginable, and a score of 0 indicated no pruritus. Orange circles indicate the aprepitant study arm; blue circles indicate the placebo study arm. Error bars indicate standard error of the mean. There was a significant difference at day 5 of P< .001 vs baseline. crossover study of aprepitant for the treatment of pruritus in patients with Sézary syndrome. The data do not support the efficacy of aprepitant as an antipruritic agent in patients with Sézary syndrome. This is in contrast to at least 7 case series that have reported an improvement in symptoms in a total of 17 patients with Sézary syndrome or mycosis fungoides. [1] [2] [3] [4] [5] This study has limitations. Although the study was randomized, blinded, and placebo controlled, the sample size was small including only 5 patients. Because pruritus can vary in patients with Sézary syndrome due to changes in disease activity and external factors such as ambient temperature and humidity, we cannot exclude the impact of these factors on the scoring of pruritus by visual analog scale. We dosed aprepitant daily for 1 week, and we cannot exclude the possibility that the results would have been different if we had used intermittent dosing.
In conclusion, in patients with Sézary syndrome, aprepitant treatment may not improve pruritus as reported in previous retrospective observational studies. The unexpected observation of worsened pruritus in patients receiving aprepitant vs placebo warrants larger prospective studies with a similar design to confirm our findings.
Program Director and Resident Perspectives on New Parent Leave in Dermatology Residency
New parent leave (NPL) has been defined as leave from work for all parents after welcoming a child regardless of how they became parents (including giving birth to a child, adoption, surrogacy, or fostering). New parent leave is essential for the wellbeing of the infant and family. Of note, the United States and Papua New Guinea are the only 2 nations in the world that do not have statutory paid leave. The purpose of this study is to test the hypothesis that administration of aprepitant 151 decreases the severity of pruritus in patients with Sézary Syndrome. 152
Design and Outcomes 153
Single center, randomized, double-blinded, placebo-controlled, crossover study design. 154
The study will examine the effect of aprepitant on pruritus in patients with Sézary Syn-155 drome. A baseline substance P level will be obtained in each subject from the serum. 156 Substance P will also be measured through tissue obtained through stored skin biopsies. 157
Subjects will be randomly allocated to one of two treatments, aprepitant or placebo. Sub-158 jects will remain on the first treatment for one week. They will then undergo a washout 159 period of one week from the first drug, and will then crossover to the other drug for a 160 one-week period. 161
Pruritus will be evaluated daily by means of a visual analogue scale (VAS), in which a 162 score of 0 indicates no pruritus and a score of 10 indicates the worst pruritus imaginable. 163
Quality of life will be evaluated by means of the Dermatology Life Quality Index (DLQI) 164 questionnaire (range, 0 to 30, higher scores indicate a worse outcome Subjects with Sézary Syndrome will be randomly allocated to receive placebo versus 184 aprepitant. Aprepitant will be administered orally in a dose of 125mg on day 1 and 80mg 185 daily on each subsequent day for a total of 7 days. After the 1week treatment period, all 186 subjects will undergo a 1week washout period from study drug. Subjects will then cross-187 over and receive the opposite study drug, again for a 7 day period. 188 189 Subjects will undergo a baseline blood draw in order to quantify the amount of substance 190 P in the serum. All patients with Sézary Syndrome are expected to have had their skin bi-191 opsied when originally diagnosed in the VUMC dermatology clinic, and substance P lev-192 els will be obtained through tissue from these stored skin biopsies. The primary endpoint is the severity of pruritus as measured on the VAS. 216
We hypothesize that administration of aprepitant will decrease the severity of pruritus in 217 patients with Sézary Syndrome compared to administration of placebo. 218 219
The secondary endpoint is the quality of life as measured on the DLQI. We hypothesize 220 that administration of aprepitant will lower the score on the quality of life index com-221 pared to administration of placebo. 222 223
Secondary Objective 224 225
We hypothesize that serum substance P concentrations correlate with substance P in the 226 skin and that circulating substance P concentrations will be elevated compared to those 227 measured in normal controls in our laboratory. Given that patients with Sézary Syndrome lack DPPIV, an enzyme known to breakdown 289 substance P, we hypothesize that decreased degradation of substance P can contribute to 290 pruritus. With evidence that substance P can contribute to pruritus, it is important to es-291 tablish whether NK1 receptor antagonism is effective in treating the condition. 292 293
The purpose of this randomized, double-blind, placebo-controlled study is to test the hy-294 pothesis that administration of aprepitant will decrease the severity of pruritus in patients 295
with Sèzary Syndrome. 296 297
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Supporting Data 298 299
Oral administration of aprepitant is FDA approved in the treatment of chemotherapy-300 induced nausea and vomiting and is administered in the dose of 125mg day 1 and 80mg 301 day 2 and 3. 9 The most common adverse effects reported in phase 3 trials include fatigue, 302 hiccups, and dyspepsia. Aprepitant as an Antipruritic Agent? 3 was case report describing the effect of aprepitant 306 on pruritus in 3 patients with Sézary Syndrome. An oral dose of 80mg daily for one week 307 was administered and pruritus was evaluated by means of a visual-analogue scale, in 308 which a score of 0 indicates no pruritus and a score of 10 indicates the worst pruritus im-309 aginable. Scores of 7, 8, and 9 dropped to 2, 3, and 2, respectively, after one day of 310 treatment, and remained the same after one week. Evaluation of quality of life was with 311 the Dermatology Life Quality Index (DLQI) questionnaire (range, 0 to 30; higher scores 312 indicate worse outcomes), resulted in scores of 22 and 17, and dropped to 8 and 4, re-313 spectively, for 2 of the 3 patients, the third patient was not evaluated with this scale. 314 315
Oral Aprepitant is Highly Efficient in the Therapy of Refractory Pruritus in 316
Erythrodermic Cutaneous T-cell Lymphoma was a small prospective, open label study 317 examining the effect of aprepitant in 5 patients with erythrodermic CTCL (3 with Sèzary 318 syndrome and 2 with erythrodermic mycosis Fungoides). Severity of pruritus was 319 assessed using a VAS, and quality of life was measured via the DLQI. A response was 320 defined as a more than 50% reduction, no response less than 25% and a partial response 321 between 25% and 50% reduction of the VAS compared to baseline. The overall response 322 rate to the aprepitant therapy was 80% with 4/5 patients demonstrating a good response. 
Study enrollment procedures 339
All patients who present to the VUMC dermatology clinic, or established patients of the 340 clinic, with biopsy proven Sèzary Syndrome will be eligible. Informed consent will be 341 obtained verbally and in writing. Subjects who meet the inclusion and exclusion criteria 342 will be enrolled. 343
Subjects will be randomly assigned to treatment using a permuted-block randomization 344 algorithm. Dr. Chang Yu, study biostatistician, will provide an allocation schedule, which 345 will be uploaded on a password-protected web site that is accessible to the investigational 346 pharmacist, but not the investigators. After subjects have been consented and screened for 347 the inclusion and exclusion criteria, investigators will document these and for the eligible 348 subjects, fax a copy of a prescription to the investigational pharmacy. The pharmacist 349 will assign the subject a randomization number from the central allocation schedule and 350 will provide the investigator with the drug. An extra label containing the randomization 351 number will be put in the subject's records. 352
If a subject declines to continue the study at any time, the study will be stopped and all 353 collected data will be withdrawn and destroyed. 354 12 NK 1 R antagonism and pruritus Version 1 04/01/11
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Study interventions 355
Interventions, Administration, and Duration
356
Following consent, each patient will undergo a baseline history and physical examination 357 (targeted to skin). A prescription will be faxed to the investigational pharmacist. An in-358 travenous catheter will be placed in the patient's forearm for blood drawing. Blood will 359 be drawn for quantification of substance P. The severity of pruritus will be quantified us-360 ing VAS (appendix). Study drug will be given orally in a dose of 125mg on day 1 and 361 80mg daily on each subsequent day for a total of 7 days. 362
Handling of Study Interventions
363
Study drug and matching placebo will be purchased by the investigational pharmacy (vs. 364 will be provided by Merck & Co.) ***Need to hear back from Merck.*** 365
Concomitant Interventions
366
Required Interventions: Subjects will be instructed to continue using any anti-pruritic 367 treatments they used prior to the initiation of study. 368 
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Criteria for intervention discontinuation 501 502
Subjects will be instructed to contact a physician associated with the study if they no 503 longer want to continue as an enrolled subject in the study. The subject will be withdrawn 504
from the study and all data will be destroyed. 505 506
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Statistical considerations 507
General Design Issues
509
The primary objective is to evaluate the effect of aprepitant on pruritus in patients with 510
Sézary Syndrome compared to administration of placebo. The study is designed as a cross-511 over between aprepitant and placebo. It is important that each subject receive both study 512 treatments, as pruritus is a subjective sensation, which may be partially relieved by place-513 bo. 514 515
The primary endpoint is a 50% reduction in pruritus as measured by the VAS. The second-516 ary endpoint is a reduction in the DLQI score. There is no pre-defined expected reduction 517 in the DLQI. Subjects will need to complete a VAS daily. To ensure compliance, subjects 518 will be instructed to complete the VAS at the same time each day and will receive a phone 519 call mid-week to ensure they are on track with the study. 520 521
The half-life of aprepitant is 9-14 hours. Using 14 hours and approximating 5 half-lives as 522 the time needed to reach steady state, it will take 3 days to reach steady state. An interven-523 tion time of one-week will be sufficient to reach steady state and experience maximal ef-524 fects of the drug. It will again take 3 days for drug washout, making a one-week washout 525 period from study drug appropriate. To evaluate the effect of administration of aprepitant on pruritus in patients with Sézary 533
Syndrome compared to administration of placebo. 534 535
The primary endpoint is the severity of pruritus as measured on the VAS. 536
We hypothesize that administration of aprepitant will decrease the severity of pruritus in 537 patients with Sézary Syndrome compared to administration of placebo. 538 539
The secondary endpoint is the quality of life as measured on the DLQI. We hypothesize 540 that administration of aprepitant will lower the score on the quality of life index com-541 pared to administration of placebo. 542 543
Secondary Objective 544 545
We hypothesize that serum substance P concentrations correlate with substance P in the 546 skin and that circulating substance P concentrations will be elevated compared to those 547 measured in normal controls in our laboratory. 548 549
Sample Size and Accrual
551
Sample size calculations were based on a paired t-test to detect a difference on the primary 552 endpoint VAS between the placebo and aprepitant treatments. In a study conducted by 553
Booken et al, 2 they reported a baseline VAS of 9.6 ± 0.9 (mean ± SD, n=5) and 4.3 ± 3.4 554 after at least 6 weeks of treatment. Based on these data and conservative assumptions of a 555 correlation of 0.5 between two repeated measures on the same subjects and a 20% placebo 556 effect, and assuming a treatment effect of 50% reduction (from 9.6 to 4.8), a sample size of 557 14 (16 need to be enrolled, assuming a 10% dropout rate) will have 83% power to detect a 558 mean difference of 2.9 (a mean of 7.7 on placebo versus a mean of 4.8 on aprepitant), us-559 ing an SD of 3.4 for the within subject difference. 560
561
Data Analyses
563
Standard graphing and screening techniques will be used to detect outliers and to ensure 564 data accuracy. Summary statistics for both continuous and categorical variables will be 565 provided by randomization groups to describe the study sample. 566
This study is a 2X2 crossover (aprepitant and placebo) study with repeated daily measure-567 19 NK 1 R antagonism and pruritus Version 1 04/01/11 ments of visual analog scale for itching and additional secondary endpoints listed above 568 during each study period. Treatment difference (i.e., aprepitant vs placebo) for each end-569 point will be estimated as within-subject mean difference along with their 95% confidence 570 intervals. A paired t-test will be performed to compare the responses. If normality of the 571 data is violated, signed rank test will be used. Even though we will make every effort to 572 minimize a carry-over effect or period effect, we will nevertheless test for these effects us-573 ing the baseline measures taken right before each study period. This evaluation will be 574 conducted using mixed-effect models and/or direct comparisons. 575
Mixed-effect models will also be used to analyze the data with a random subject effect and 576 with treatment (aprepitant versus placebo) and time trend as fixed effects. We might also 577 include baseline covariates which are potential confounders in the mixed-effect models to 578 adjust for their effects. We will explore different plausible covariance matrices, such as 579 compound symmetry and a first-order autoregressive process [AR (1) analysis for other continuous endpoints will be conducted similarly. 584
Based on our past experience, we anticipate a drop-out rate of 10% or less. Subjects who 585 drop out prior to completing study period 2 will be replaced. We will also keep the period 586 one data collected on the replaced subject. If data are missing for an isolated time point 587 during one of the study periods, mixed-effect models are robust in the sense that they can 588 include subjects with missing data at some time points but not all time points to estimate 589 the effects of interest. However, we will conservatively impute missing data to perform 590 analyses with and without missing data to corroborate our findings. 591
Specific inferences on effects of interest will be made by reporting a point estimate along 592 with a 95% confidence interval and the p value. Hypotheses will be tested at the level of 593 =0.05. This data analysis plan will be carried out using statistical software SPSS The protocols and any amendments will be reviewed and approved by the Vanderbilt In-602 stitutional Review Board before any subject is enrolled. The PI will closely oversee the 603 protocol in conjunction with the research fellow and dedicated research nurses. Any ad-604 verse events or toxicities will be reported to the IRB as per IRB guidelines. Any unto-605 ward medical event will be classified as an adverse event, regardless of its causal rela-606 tionship with the study. An adverse event will be classified as serious if it a) results in 607 death, b) is life-threatening, c) requires inpatient hospitalization, or prolongation of exist-608
